- GSK Canada has received approval for a new prefilled syringe presentation of Shingrix (recombinant zoster vaccine) in Canada, eliminating the need to reconstitute separate vials before administration and simplifying the vaccination process for healthcare professionals.
- The approval is supported by data confirming technical comparability between the new and existing presentations. The prefilled syringe is expected to become available across Canada in early 2027.
- The new presentation retains Shingrix’s existing Canadian indications for preventing shingles in adults aged 50 years and older, and in adults 18 years and older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by disease or therapy.
- The prefilled syringe presentation has also been approved in the US and Europe. GSK says the new format is designed to improve ease of administration and support efforts to increase adult immunization rates.
Takeaways:
GSK’s prefilled Shingrix syringe should improve operational convenience for clinics and pharmacies by removing the reconstitution step, which can reduce preparation time, handling complexity, and the chance of administration friction. That makes it easier to scale adult shingles vaccination in Canada, especially in busy settings, and it could modestly support uptake by making the product simpler to stock and give.
Source: CA Newswire
